JP2002534995A5 - - Google Patents

Download PDF

Info

Publication number
JP2002534995A5
JP2002534995A5 JP2000595705A JP2000595705A JP2002534995A5 JP 2002534995 A5 JP2002534995 A5 JP 2002534995A5 JP 2000595705 A JP2000595705 A JP 2000595705A JP 2000595705 A JP2000595705 A JP 2000595705A JP 2002534995 A5 JP2002534995 A5 JP 2002534995A5
Authority
JP
Japan
Prior art keywords
xaa
leu
pro
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000595705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002534995A (ja
Filing date
Publication date
Priority claimed from US09/234,208 external-priority patent/US7393823B1/en
Application filed filed Critical
Publication of JP2002534995A publication Critical patent/JP2002534995A/ja
Publication of JP2002534995A5 publication Critical patent/JP2002534995A5/ja
Pending legal-status Critical Current

Links

JP2000595705A 1999-01-20 2000-01-20 Ｈｅｒ−２結合アンタゴニスト Pending JP2002534995A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/234,208 US7393823B1 (en) 1999-01-20 1999-01-20 HER-2 binding antagonists
US09/234,208 1999-01-20
PCT/US2000/001484 WO2000044403A1 (en) 1999-01-20 2000-01-20 Her-2 binding antagonists

Publications (2)

Publication Number Publication Date
JP2002534995A JP2002534995A (ja) 2002-10-22
JP2002534995A5 true JP2002534995A5 (enExample) 2007-11-15

Family

ID=22880399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000595705A Pending JP2002534995A (ja) 1999-01-20 2000-01-20 Ｈｅｒ−２結合アンタゴニスト

Country Status (6)

Country Link
US (4) US7393823B1 (enExample)
EP (1) EP1144004A4 (enExample)
JP (1) JP2002534995A (enExample)
AU (1) AU777422B2 (enExample)
CA (1) CA2361181C (enExample)
WO (1) WO2000044403A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US6294349B1 (en) 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
EP1189931B1 (en) 1999-07-02 2006-06-21 Genentech, Inc. Peptide compounds that bind her2
US6435873B1 (en) 2000-10-10 2002-08-20 3M Innovative Properties Company Medication delivery devices
WO2003014159A1 (en) * 2001-08-03 2003-02-20 Commonwealth Scientific And Industrial Research Organisation Methods of screening based on the egf receptor crystal structure
WO2004005320A2 (en) * 2002-07-03 2004-01-15 The Curators Of The University Of Missouri ErbB-2 RECEPTOR TARGETING PEPTIDE
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
EP1745073A2 (en) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
AU2006315825A1 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
AU2007257683A1 (en) * 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
WO2008005983A2 (en) * 2006-07-06 2008-01-10 Molecular Logix, Inc. Pan-her antagonists and methods of use
RU2010119556A (ru) * 2007-10-16 2011-11-27 Симфоген А/С (Dk) Композиции, содержащие оптимизированные мультимеры her1 и her3, и способы их применения
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
AU2014318566A1 (en) * 2013-09-12 2016-04-07 Thomas Jefferson University Novel delivery compositions and methods of using same
US11484505B2 (en) 2016-10-13 2022-11-01 Thomas Jefferson University Delivery compositions, and methods of making and using same
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2024186690A2 (en) 2023-03-03 2024-09-12 Enosi Therapeutics Corporation Oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
EP0119528B1 (en) 1983-03-11 1992-05-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human renal cancer antigens and method
WO1985003357A1 (en) 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
ATE130873T1 (de) 1988-04-18 1995-12-15 Applied Biotechnology Inc Nachweis der expression von neu genen und produkten.
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
DE69033842T2 (de) 1989-08-04 2002-06-20 Schering Ag Äusserliche domäne von c-erbb-2:gp75
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
ATE153858T1 (de) 1990-04-06 1997-06-15 Univ Pennsylvania Ligand für das neu-gen-produkt
US5874528A (en) 1990-05-25 1999-02-23 Georgetown University Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2 receptor
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE221915T1 (de) 1991-02-22 2002-08-15 American Cyanamid Co Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ATE278019T1 (de) 1991-06-21 2004-10-15 Inst Medical W & E Hall Neuartige rezeptor-typ tyrosinkinase und deren verwendung
WO1993003741A1 (en) 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
CA2127540A1 (en) 1992-01-09 1993-07-22 Juha Partanen Tie, a novel endothelial cell receptor tyrosine kinase
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
EP0750516A4 (en) 1993-03-26 1998-07-01 Univ Jefferson METHOD FOR INHIBITING CELL PROLIFERATION AND TRIGGERING CELL DIFFERENTIATION USING TYPE 1 GROWTH FACTOR RECEPTOR OLIGONUCLEOTIDES
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US6045797A (en) 1994-03-14 2000-04-04 New York University Medical Center Treatment or diagnosis of diseases or conditions associated with a BLM domain
WO1995025166A1 (en) 1994-03-14 1995-09-21 New York University Medical Center Methods for treatment or diagnosis of diseases or conditions associated with abnormal signal transduction
WO1995030331A1 (en) 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US5770567A (en) 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
HRP950558A2 (en) 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
CA2259157A1 (en) 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0928203B1 (en) 1996-09-24 2006-10-25 Merck & Co., Inc. Compounds for the inhibition of angiogenesis by gene therapy
US5910583A (en) 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US7125969B1 (en) 1996-11-27 2006-10-24 The Regents Of The University Of California ETS-related gene overexpressed in human breast and epithelial cancers
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4405597B2 (ja) 1997-06-18 2010-01-27 メルク エンド カムパニー インコーポレーテッド ヒト受容体型チロシンキナーゼｋｄｒ
EP1023605A1 (en) 1997-10-15 2000-08-02 Abbott Laboratories Methods and compositions for detecting hepatitis e virus
AU2581599A (en) 1998-02-04 1999-08-23 Genentech Inc. Use of heregulin as an epithelial cell growth factor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1308455B9 (en) 1998-05-06 2006-06-14 Genentech, Inc. A composition comprising anti-HER2 antibodies
US7125959B2 (en) 1998-05-15 2006-10-24 Genentech, Inc. PRO4405 polypeptides
EP1084245B1 (en) 1998-06-11 2006-03-29 AstraZeneca AB Human receptor tyrosine kinase
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
IL142684A0 (en) 1998-11-07 2002-03-10 Genentech Inc Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
EP1189931B1 (en) 1999-07-02 2006-06-21 Genentech, Inc. Peptide compounds that bind her2
CA2384264A1 (en) 1999-10-15 2001-04-26 Human Genome Sciences, Inc. Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
AU2001295002B2 (en) 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US6780912B2 (en) 2001-02-26 2004-08-24 Hewlett-Packard Development Company L.P. Addition of metal ions to improve lightfastness of inkjet inks
AU2002251367A1 (en) 2001-05-03 2002-11-18 Oxford Glycosciences (Uk) Ltd Proteins and genes for diagnosis and treatment of erbb2-related cancer
WO2002097114A2 (en) 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
JP2005532780A (ja) 2001-09-19 2005-11-04 インタージェネティックス インコーポレイテッド 発癌リスク層別化のための遺伝的解析
WO2003035843A2 (en) 2001-10-25 2003-05-01 Buck Institute For Age Research Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
JP2005525317A (ja) 2002-01-18 2005-08-25 カイロン コーポレイション Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US20050239088A1 (en) 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
CN100392074C (zh) 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途

Similar Documents

Publication Publication Date Title
CA2399387C (en) Heterologous polypeptide of the tnf family
Yamauchi et al. Purification and molecular cloning of prostacyclin-stimulating factor from serum-free conditioned medium of human diploid fibroblast cells
CA2361181A1 (en) Her-2 binding antagonists
US10695404B2 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
AU2001234953A1 (en) Heterologous polypeptide of the TNF family
JP2010000082A (ja) Ｉｇｆ−１レセプターと相互作用するタンパク質、それをコードする遺伝子及びそれらの使用
EP1534320A2 (en) Apolipoprotein l-i for the treatment or diagnosis of trypanosomal diseases
JP2008521444A5 (enExample)
JP2004501605A5 (enExample)
WO2005112969A2 (en) Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
CA2319715A1 (en) Breast cancer resistance protein (bcrp) and the dna which encodes it
JP2006325596A (ja) シアロアドヘシンファミリーメンバー−２（ｓａｆ−２）
IL139852A (en) Monoclonal antibodies directed against the g3bp protein, and uses
JP2001509372A (ja) 血小板凝集に関与する細胞表面受容体であるヒトｆ１１抗原
US8735355B2 (en) Methods of use of fragments of secreted frizzled related protein, sFRP
US6114515A (en) PIGRL-1, a member of immunoglobulin gene superfamily
WO2001009368A1 (en) Follistatin antagonists
JP2002527037A (ja) サイトカインファミリーメンバーｅｆ−７
TOBE et al. Amino Acid Sequences of 60B8 Antigens Induced in HL-60 Cells by 1, 25-Dihydroxyvitamin D3: The Antigens Are Identical with Macrophage-Related Protein-14 and-8
Ahlsen et al. A 30-kDa fragment of insulin-like growth factor (IGF) binding protein-3 in human pregnancy serum with strongly reduced IGF-I binding
JP2002513548A (ja) サイトカインファミリーメンバー２−１９
LT4877B (lt) Prv-1 genas ir jo panaudojimas
WO2001064879A2 (en) G-proteins coupled receptor related polypeptides
JP2002281987A (ja) Ｓｂｐｅｒｒ４ポリペプチドおよびポリヌクレオチド
WO2004028555A1 (en) Resistin binding proteins, their preparation and use